nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Thiotepa—sarcoma	0.095	0.458	CbGbCtD
Pimecrolimus—CYP3A4—Mitoxantrone—sarcoma	0.0408	0.197	CbGbCtD
Pimecrolimus—CYP3A4—Vincristine—sarcoma	0.0281	0.136	CbGbCtD
Pimecrolimus—CYP3A4—Etoposide—sarcoma	0.0258	0.124	CbGbCtD
Pimecrolimus—MTOR—leg—sarcoma	0.0243	0.108	CbGeAlD
Pimecrolimus—MTOR—forelimb—sarcoma	0.0242	0.107	CbGeAlD
Pimecrolimus—MTOR—hindlimb—sarcoma	0.0217	0.0965	CbGeAlD
Pimecrolimus—MTOR—appendage—sarcoma	0.0186	0.0828	CbGeAlD
Pimecrolimus—CYP3A4—Doxorubicin—sarcoma	0.0176	0.0848	CbGbCtD
Pimecrolimus—MTOR—mammary gland—sarcoma	0.00907	0.0403	CbGeAlD
Pimecrolimus—FKBP1A—mammary gland—sarcoma	0.00816	0.0362	CbGeAlD
Pimecrolimus—MTOR—myometrium—sarcoma	0.00644	0.0286	CbGeAlD
Pimecrolimus—MTOR—embryo—sarcoma	0.00619	0.0275	CbGeAlD
Pimecrolimus—MTOR—seminal vesicle—sarcoma	0.00582	0.0258	CbGeAlD
Pimecrolimus—FKBP1A—myometrium—sarcoma	0.00579	0.0257	CbGeAlD
Pimecrolimus—MTOR—hematopoietic system—sarcoma	0.00553	0.0245	CbGeAlD
Pimecrolimus—MTOR—connective tissue—sarcoma	0.00532	0.0236	CbGeAlD
Pimecrolimus—FKBP1A—seminal vesicle—sarcoma	0.00523	0.0232	CbGeAlD
Pimecrolimus—FKBP1A—hematopoietic system—sarcoma	0.00497	0.0221	CbGeAlD
Pimecrolimus—MTOR—smooth muscle tissue—sarcoma	0.00487	0.0216	CbGeAlD
Pimecrolimus—MTOR—skin of body—sarcoma	0.00481	0.0213	CbGeAlD
Pimecrolimus—FKBP1A—connective tissue—sarcoma	0.00479	0.0213	CbGeAlD
Pimecrolimus—FKBP1A—smooth muscle tissue—sarcoma	0.00438	0.0194	CbGeAlD
Pimecrolimus—FKBP1A—skin of body—sarcoma	0.00432	0.0192	CbGeAlD
Pimecrolimus—MTOR—uterus—sarcoma	0.00418	0.0185	CbGeAlD
Pimecrolimus—MTOR—lymphoid tissue—sarcoma	0.00389	0.0173	CbGeAlD
Pimecrolimus—FKBP1A—cardiac atrium—sarcoma	0.00378	0.0168	CbGeAlD
Pimecrolimus—FKBP1A—uterus—sarcoma	0.00376	0.0167	CbGeAlD
Pimecrolimus—MTOR—tendon—sarcoma	0.00366	0.0162	CbGeAlD
Pimecrolimus—MTOR—bone marrow—sarcoma	0.00354	0.0157	CbGeAlD
Pimecrolimus—FKBP1A—lymphoid tissue—sarcoma	0.0035	0.0155	CbGeAlD
Pimecrolimus—FKBP1A—tendon—sarcoma	0.00329	0.0146	CbGeAlD
Pimecrolimus—FKBP1A—bone marrow—sarcoma	0.00319	0.0142	CbGeAlD
Pimecrolimus—MTOR—testis—sarcoma	0.00303	0.0135	CbGeAlD
Pimecrolimus—MTOR—liver—sarcoma	0.00286	0.0127	CbGeAlD
Pimecrolimus—FKBP1A—testis—sarcoma	0.00272	0.0121	CbGeAlD
Pimecrolimus—FKBP1A—liver—sarcoma	0.00258	0.0114	CbGeAlD
Pimecrolimus—MTOR—lymph node—sarcoma	0.0022	0.00975	CbGeAlD
Pimecrolimus—FKBP1A—lymph node—sarcoma	0.00198	0.00877	CbGeAlD
Pimecrolimus—CYP3A4—hematopoietic system—sarcoma	0.00162	0.00722	CbGeAlD
Pimecrolimus—Infestation NOS—Thiotepa—sarcoma	0.00127	0.0048	CcSEcCtD
Pimecrolimus—Infestation—Thiotepa—sarcoma	0.00127	0.0048	CcSEcCtD
Pimecrolimus—Pneumonia—Dactinomycin—sarcoma	0.00126	0.00479	CcSEcCtD
Pimecrolimus—Conjunctivitis—Thiotepa—sarcoma	0.00123	0.00466	CcSEcCtD
Pimecrolimus—Epistaxis—Thiotepa—sarcoma	0.00119	0.00453	CcSEcCtD
Pimecrolimus—Otitis media—Epirubicin—sarcoma	0.00117	0.00444	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Vincristine—sarcoma	0.00115	0.00436	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Mitoxantrone—sarcoma	0.00114	0.00432	CcSEcCtD
Pimecrolimus—Pneumonia—Vincristine—sarcoma	0.00113	0.00428	CcSEcCtD
Pimecrolimus—Pharyngitis—Dactinomycin—sarcoma	0.00112	0.00424	CcSEcCtD
Pimecrolimus—Pneumonia—Mitoxantrone—sarcoma	0.0011	0.00417	CcSEcCtD
Pimecrolimus—Otitis media—Doxorubicin—sarcoma	0.00108	0.00411	CcSEcCtD
Pimecrolimus—Neoplasm malignant—Epirubicin—sarcoma	0.00107	0.00405	CcSEcCtD
Pimecrolimus—Conjunctivitis—Mitoxantrone—sarcoma	0.00106	0.00403	CcSEcCtD
Pimecrolimus—Eye disorder—Thiotepa—sarcoma	0.00106	0.00403	CcSEcCtD
Pimecrolimus—Flushing—Dactinomycin—sarcoma	0.00105	0.00397	CcSEcCtD
Pimecrolimus—Immune system disorder—Thiotepa—sarcoma	0.00103	0.00389	CcSEcCtD
Pimecrolimus—Sinusitis—Mitoxantrone—sarcoma	0.00103	0.00389	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Thiotepa—sarcoma	0.00102	0.00388	CcSEcCtD
Pimecrolimus—Viral infection—Epirubicin—sarcoma	0.00101	0.00382	CcSEcCtD
Pimecrolimus—Skin discolouration—Epirubicin—sarcoma	0.00101	0.00382	CcSEcCtD
Pimecrolimus—Bone disorder—Epirubicin—sarcoma	0.00101	0.00382	CcSEcCtD
Pimecrolimus—Malnutrition—Thiotepa—sarcoma	0.000989	0.00375	CcSEcCtD
Pimecrolimus—Erythema—Thiotepa—sarcoma	0.000989	0.00375	CcSEcCtD
Pimecrolimus—Herpes simplex—Epirubicin—sarcoma	0.000988	0.00375	CcSEcCtD
Pimecrolimus—Neoplasm malignant—Doxorubicin—sarcoma	0.000987	0.00374	CcSEcCtD
Pimecrolimus—Rhinitis—Mitoxantrone—sarcoma	0.000984	0.00373	CcSEcCtD
Pimecrolimus—Erythema—Dactinomycin—sarcoma	0.000981	0.00372	CcSEcCtD
Pimecrolimus—Pharyngitis—Mitoxantrone—sarcoma	0.000974	0.00369	CcSEcCtD
Pimecrolimus—Back pain—Thiotepa—sarcoma	0.000957	0.00363	CcSEcCtD
Pimecrolimus—Viral infection—Doxorubicin—sarcoma	0.000933	0.00354	CcSEcCtD
Pimecrolimus—Skin discolouration—Doxorubicin—sarcoma	0.000933	0.00354	CcSEcCtD
Pimecrolimus—Bone disorder—Doxorubicin—sarcoma	0.000933	0.00354	CcSEcCtD
Pimecrolimus—Herpes simplex—Doxorubicin—sarcoma	0.000915	0.00347	CcSEcCtD
Pimecrolimus—Pneumonia—Etoposide—sarcoma	0.000914	0.00347	CcSEcCtD
Pimecrolimus—Infestation NOS—Etoposide—sarcoma	0.000909	0.00345	CcSEcCtD
Pimecrolimus—Infestation—Etoposide—sarcoma	0.000909	0.00345	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Vincristine—sarcoma	0.000908	0.00344	CcSEcCtD
Pimecrolimus—Influenza like illness—Epirubicin—sarcoma	0.000885	0.00335	CcSEcCtD
Pimecrolimus—Skin exfoliation—Epirubicin—sarcoma	0.00087	0.0033	CcSEcCtD
Pimecrolimus—Cough—Thiotepa—sarcoma	0.000863	0.00327	CcSEcCtD
Pimecrolimus—Erythema—Mitoxantrone—sarcoma	0.000854	0.00324	CcSEcCtD
Pimecrolimus—Back pain—Vincristine—sarcoma	0.000848	0.00322	CcSEcCtD
Pimecrolimus—Arthralgia—Thiotepa—sarcoma	0.000842	0.00319	CcSEcCtD
Pimecrolimus—CYP3A4—liver—sarcoma	0.000842	0.00374	CbGeAlD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000836	0.00317	CcSEcCtD
Pimecrolimus—Back pain—Mitoxantrone—sarcoma	0.000826	0.00313	CcSEcCtD
Pimecrolimus—Influenza like illness—Doxorubicin—sarcoma	0.000818	0.0031	CcSEcCtD
Pimecrolimus—Skin exfoliation—Doxorubicin—sarcoma	0.000805	0.00305	CcSEcCtD
Pimecrolimus—Infection—Thiotepa—sarcoma	0.000802	0.00304	CcSEcCtD
Pimecrolimus—Oedema—Dactinomycin—sarcoma	0.000801	0.00304	CcSEcCtD
Pimecrolimus—Infection—Dactinomycin—sarcoma	0.000796	0.00302	CcSEcCtD
Pimecrolimus—Nervous system disorder—Thiotepa—sarcoma	0.000791	0.003	CcSEcCtD
Pimecrolimus—Skin disorder—Thiotepa—sarcoma	0.000784	0.00297	CcSEcCtD
Pimecrolimus—Eye disorder—Etoposide—sarcoma	0.000763	0.00289	CcSEcCtD
Pimecrolimus—Flushing—Etoposide—sarcoma	0.000757	0.00287	CcSEcCtD
Pimecrolimus—Cough—Mitoxantrone—sarcoma	0.000745	0.00283	CcSEcCtD
Pimecrolimus—Immune system disorder—Etoposide—sarcoma	0.000737	0.0028	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Etoposide—sarcoma	0.000735	0.00279	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000735	0.00279	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00073	0.00277	CcSEcCtD
Pimecrolimus—Arthralgia—Mitoxantrone—sarcoma	0.000727	0.00276	CcSEcCtD
Pimecrolimus—Paraesthesia—Thiotepa—sarcoma	0.000725	0.00275	CcSEcCtD
Pimecrolimus—Oedema—Vincristine—sarcoma	0.000716	0.00271	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Vincristine—sarcoma	0.000716	0.00271	CcSEcCtD
Pimecrolimus—Infection—Vincristine—sarcoma	0.000711	0.0027	CcSEcCtD
Pimecrolimus—Nervous system disorder—Vincristine—sarcoma	0.000702	0.00266	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Epirubicin—sarcoma	0.000701	0.00266	CcSEcCtD
Pimecrolimus—Oedema—Mitoxantrone—sarcoma	0.000697	0.00264	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Mitoxantrone—sarcoma	0.000697	0.00264	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Thiotepa—sarcoma	0.000697	0.00264	CcSEcCtD
Pimecrolimus—Infection—Mitoxantrone—sarcoma	0.000692	0.00263	CcSEcCtD
Pimecrolimus—Pain—Thiotepa—sarcoma	0.00069	0.00262	CcSEcCtD
Pimecrolimus—Constipation—Thiotepa—sarcoma	0.00069	0.00262	CcSEcCtD
Pimecrolimus—Back pain—Etoposide—sarcoma	0.000687	0.00261	CcSEcCtD
Pimecrolimus—Pain—Dactinomycin—sarcoma	0.000685	0.0026	CcSEcCtD
Pimecrolimus—Skin disorder—Mitoxantrone—sarcoma	0.000677	0.00257	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Thiotepa—sarcoma	0.00066	0.0025	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dactinomycin—sarcoma	0.000655	0.00248	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Vincristine—sarcoma	0.000652	0.00247	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Doxorubicin—sarcoma	0.000648	0.00246	CcSEcCtD
Pimecrolimus—Paraesthesia—Vincristine—sarcoma	0.000643	0.00244	CcSEcCtD
Pimecrolimus—Urticaria—Thiotepa—sarcoma	0.000641	0.00243	CcSEcCtD
Pimecrolimus—Face oedema—Epirubicin—sarcoma	0.000638	0.00242	CcSEcCtD
Pimecrolimus—Abdominal pain—Thiotepa—sarcoma	0.000638	0.00242	CcSEcCtD
Pimecrolimus—Body temperature increased—Thiotepa—sarcoma	0.000638	0.00242	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000635	0.00241	CcSEcCtD
Pimecrolimus—Abdominal pain—Dactinomycin—sarcoma	0.000633	0.0024	CcSEcCtD
Pimecrolimus—Body temperature increased—Dactinomycin—sarcoma	0.000633	0.0024	CcSEcCtD
Pimecrolimus—Paraesthesia—Mitoxantrone—sarcoma	0.000626	0.00237	CcSEcCtD
Pimecrolimus—Dyspnoea—Mitoxantrone—sarcoma	0.000621	0.00236	CcSEcCtD
Pimecrolimus—Cough—Etoposide—sarcoma	0.00062	0.00235	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Vincristine—sarcoma	0.000618	0.00234	CcSEcCtD
Pimecrolimus—Pain—Vincristine—sarcoma	0.000612	0.00232	CcSEcCtD
Pimecrolimus—Constipation—Vincristine—sarcoma	0.000612	0.00232	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Epirubicin—sarcoma	0.000604	0.00229	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000601	0.00228	CcSEcCtD
Pimecrolimus—Breast disorder—Epirubicin—sarcoma	0.000597	0.00227	CcSEcCtD
Pimecrolimus—Constipation—Mitoxantrone—sarcoma	0.000596	0.00226	CcSEcCtD
Pimecrolimus—Pain—Mitoxantrone—sarcoma	0.000596	0.00226	CcSEcCtD
Pimecrolimus—Hypersensitivity—Thiotepa—sarcoma	0.000595	0.00225	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Epirubicin—sarcoma	0.000591	0.00224	CcSEcCtD
Pimecrolimus—Face oedema—Doxorubicin—sarcoma	0.000591	0.00224	CcSEcCtD
Pimecrolimus—Hypersensitivity—Dactinomycin—sarcoma	0.00059	0.00224	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Vincristine—sarcoma	0.000585	0.00222	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Etoposide—sarcoma	0.00058	0.0022	CcSEcCtD
Pimecrolimus—Infection—Etoposide—sarcoma	0.000576	0.00218	CcSEcCtD
Pimecrolimus—Influenza—Epirubicin—sarcoma	0.000571	0.00217	CcSEcCtD
Pimecrolimus—Asthma—Epirubicin—sarcoma	0.000571	0.00217	CcSEcCtD
Pimecrolimus—Pruritus—Thiotepa—sarcoma	0.000571	0.00217	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00057	0.00216	CcSEcCtD
Pimecrolimus—Body temperature increased—Vincristine—sarcoma	0.000566	0.00215	CcSEcCtD
Pimecrolimus—Abdominal pain—Vincristine—sarcoma	0.000566	0.00215	CcSEcCtD
Pimecrolimus—Skin disorder—Etoposide—sarcoma	0.000563	0.00214	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Doxorubicin—sarcoma	0.000559	0.00212	CcSEcCtD
Pimecrolimus—Urticaria—Mitoxantrone—sarcoma	0.000554	0.0021	CcSEcCtD
Pimecrolimus—Breast disorder—Doxorubicin—sarcoma	0.000553	0.0021	CcSEcCtD
Pimecrolimus—Diarrhoea—Thiotepa—sarcoma	0.000552	0.00209	CcSEcCtD
Pimecrolimus—Abdominal pain—Mitoxantrone—sarcoma	0.000551	0.00209	CcSEcCtD
Pimecrolimus—Body temperature increased—Mitoxantrone—sarcoma	0.000551	0.00209	CcSEcCtD
Pimecrolimus—Bronchitis—Epirubicin—sarcoma	0.00055	0.00208	CcSEcCtD
Pimecrolimus—Diarrhoea—Dactinomycin—sarcoma	0.000548	0.00208	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—sarcoma	0.000547	0.00207	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Epirubicin—sarcoma	0.000531	0.00201	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—sarcoma	0.000529	0.00201	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—sarcoma	0.000529	0.00201	CcSEcCtD
Pimecrolimus—Hypersensitivity—Vincristine—sarcoma	0.000527	0.002	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Epirubicin—sarcoma	0.000522	0.00198	CcSEcCtD
Pimecrolimus—Paraesthesia—Etoposide—sarcoma	0.000521	0.00197	CcSEcCtD
Pimecrolimus—Dyspnoea—Etoposide—sarcoma	0.000517	0.00196	CcSEcCtD
Pimecrolimus—Hypersensitivity—Mitoxantrone—sarcoma	0.000514	0.00195	CcSEcCtD
Pimecrolimus—Vomiting—Thiotepa—sarcoma	0.000513	0.00195	CcSEcCtD
Pimecrolimus—Pneumonia—Epirubicin—sarcoma	0.000512	0.00194	CcSEcCtD
Pimecrolimus—Infestation NOS—Epirubicin—sarcoma	0.00051	0.00193	CcSEcCtD
Pimecrolimus—Infestation—Epirubicin—sarcoma	0.00051	0.00193	CcSEcCtD
Pimecrolimus—Vomiting—Dactinomycin—sarcoma	0.000509	0.00193	CcSEcCtD
Pimecrolimus—Rash—Thiotepa—sarcoma	0.000509	0.00193	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—sarcoma	0.000509	0.00193	CcSEcCtD
Pimecrolimus—Dermatitis—Thiotepa—sarcoma	0.000508	0.00193	CcSEcCtD
Pimecrolimus—Headache—Thiotepa—sarcoma	0.000506	0.00192	CcSEcCtD
Pimecrolimus—Rash—Dactinomycin—sarcoma	0.000505	0.00192	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Etoposide—sarcoma	0.000501	0.0019	CcSEcCtD
Pimecrolimus—Pain—Etoposide—sarcoma	0.000496	0.00188	CcSEcCtD
Pimecrolimus—Constipation—Etoposide—sarcoma	0.000496	0.00188	CcSEcCtD
Pimecrolimus—Conjunctivitis—Epirubicin—sarcoma	0.000495	0.00188	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000491	0.00186	CcSEcCtD
Pimecrolimus—Diarrhoea—Vincristine—sarcoma	0.00049	0.00186	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—sarcoma	0.000483	0.00183	CcSEcCtD
Pimecrolimus—Epistaxis—Epirubicin—sarcoma	0.000481	0.00182	CcSEcCtD
Pimecrolimus—Nausea—Thiotepa—sarcoma	0.000479	0.00182	CcSEcCtD
Pimecrolimus—Sinusitis—Epirubicin—sarcoma	0.000478	0.00181	CcSEcCtD
Pimecrolimus—Diarrhoea—Mitoxantrone—sarcoma	0.000477	0.00181	CcSEcCtD
Pimecrolimus—Nausea—Dactinomycin—sarcoma	0.000476	0.0018	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—sarcoma	0.000474	0.0018	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Etoposide—sarcoma	0.000474	0.0018	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—sarcoma	0.000471	0.00179	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—sarcoma	0.000471	0.00179	CcSEcCtD
Pimecrolimus—Urticaria—Etoposide—sarcoma	0.000461	0.00175	CcSEcCtD
Pimecrolimus—Rhinitis—Epirubicin—sarcoma	0.000459	0.00174	CcSEcCtD
Pimecrolimus—Body temperature increased—Etoposide—sarcoma	0.000458	0.00174	CcSEcCtD
Pimecrolimus—Abdominal pain—Etoposide—sarcoma	0.000458	0.00174	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—sarcoma	0.000458	0.00174	CcSEcCtD
Pimecrolimus—Vomiting—Vincristine—sarcoma	0.000455	0.00173	CcSEcCtD
Pimecrolimus—Pharyngitis—Epirubicin—sarcoma	0.000454	0.00172	CcSEcCtD
Pimecrolimus—Rash—Vincristine—sarcoma	0.000451	0.00171	CcSEcCtD
Pimecrolimus—Dermatitis—Vincristine—sarcoma	0.000451	0.00171	CcSEcCtD
Pimecrolimus—Headache—Vincristine—sarcoma	0.000448	0.0017	CcSEcCtD
Pimecrolimus—Epistaxis—Doxorubicin—sarcoma	0.000445	0.00169	CcSEcCtD
Pimecrolimus—Vomiting—Mitoxantrone—sarcoma	0.000443	0.00168	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—sarcoma	0.000442	0.00168	CcSEcCtD
Pimecrolimus—Rash—Mitoxantrone—sarcoma	0.000439	0.00167	CcSEcCtD
Pimecrolimus—Dermatitis—Mitoxantrone—sarcoma	0.000439	0.00166	CcSEcCtD
Pimecrolimus—Headache—Mitoxantrone—sarcoma	0.000437	0.00166	CcSEcCtD
Pimecrolimus—Eye disorder—Epirubicin—sarcoma	0.000427	0.00162	CcSEcCtD
Pimecrolimus—Hypersensitivity—Etoposide—sarcoma	0.000427	0.00162	CcSEcCtD
Pimecrolimus—Nausea—Vincristine—sarcoma	0.000425	0.00161	CcSEcCtD
Pimecrolimus—Flushing—Epirubicin—sarcoma	0.000425	0.00161	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—sarcoma	0.000424	0.00161	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—sarcoma	0.00042	0.00159	CcSEcCtD
Pimecrolimus—Nausea—Mitoxantrone—sarcoma	0.000414	0.00157	CcSEcCtD
Pimecrolimus—Immune system disorder—Epirubicin—sarcoma	0.000413	0.00157	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Epirubicin—sarcoma	0.000412	0.00156	CcSEcCtD
Pimecrolimus—Pruritus—Etoposide—sarcoma	0.00041	0.00156	CcSEcCtD
Pimecrolimus—Malnutrition—Epirubicin—sarcoma	0.000398	0.00151	CcSEcCtD
Pimecrolimus—Erythema—Epirubicin—sarcoma	0.000398	0.00151	CcSEcCtD
Pimecrolimus—Diarrhoea—Etoposide—sarcoma	0.000397	0.0015	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—sarcoma	0.000396	0.0015	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—sarcoma	0.000393	0.00149	CcSEcCtD
Pimecrolimus—Back pain—Epirubicin—sarcoma	0.000385	0.00146	CcSEcCtD
Pimecrolimus—Immune system disorder—Doxorubicin—sarcoma	0.000382	0.00145	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—sarcoma	0.000381	0.00145	CcSEcCtD
Pimecrolimus—Vomiting—Etoposide—sarcoma	0.000369	0.0014	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—sarcoma	0.000368	0.0014	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—sarcoma	0.000368	0.0014	CcSEcCtD
Pimecrolimus—Rash—Etoposide—sarcoma	0.000366	0.00139	CcSEcCtD
Pimecrolimus—Dermatitis—Etoposide—sarcoma	0.000365	0.00138	CcSEcCtD
Pimecrolimus—Headache—Etoposide—sarcoma	0.000363	0.00138	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—sarcoma	0.000356	0.00135	CcSEcCtD
Pimecrolimus—Cough—Epirubicin—sarcoma	0.000347	0.00132	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000345	0.00113	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—HRAS—sarcoma	0.000345	0.00113	CbGpPWpGaD
Pimecrolimus—Nausea—Etoposide—sarcoma	0.000344	0.00131	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—sarcoma	0.000341	0.00112	CbGpPWpGaD
Pimecrolimus—Arthralgia—Epirubicin—sarcoma	0.000339	0.00129	CcSEcCtD
Pimecrolimus—MTOR—Insulin Signaling—JUN—sarcoma	0.000338	0.00111	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000337	0.00128	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—SRC—sarcoma	0.000336	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—JUN—sarcoma	0.000335	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—HRAS—sarcoma	0.000332	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—HRAS—sarcoma	0.000332	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—MDM2—sarcoma	0.000332	0.00109	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TLE1—sarcoma	0.000331	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—SRC—sarcoma	0.00033	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PLCG1—sarcoma	0.000328	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—KRAS—sarcoma	0.000327	0.00108	CbGpPWpGaD
Pimecrolimus—Oedema—Epirubicin—sarcoma	0.000325	0.00123	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Epirubicin—sarcoma	0.000325	0.00123	CcSEcCtD
Pimecrolimus—MTOR—Signaling by Insulin receptor—KRAS—sarcoma	0.000325	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—NRAS—sarcoma	0.000323	0.00106	CbGpPWpGaD
Pimecrolimus—Infection—Epirubicin—sarcoma	0.000323	0.00122	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—sarcoma	0.000322	0.00122	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—PTPRC—sarcoma	0.000321	0.00106	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Epirubicin—sarcoma	0.000319	0.00121	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—sarcoma	0.000318	0.00105	CbGpPWpGaD
Pimecrolimus—Skin disorder—Epirubicin—sarcoma	0.000316	0.0012	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—PLCG1—sarcoma	0.000315	0.00104	CbGpPWpGaD
Pimecrolimus—Arthralgia—Doxorubicin—sarcoma	0.000314	0.00119	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—PLCG1—sarcoma	0.000313	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—sarcoma	0.000313	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JUN—sarcoma	0.000312	0.00103	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000312	0.00118	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—ATF1—sarcoma	0.000311	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KIT—sarcoma	0.00031	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.00031	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—NRAS—sarcoma	0.000309	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—NRAS—sarcoma	0.000304	0.001	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—SRC—sarcoma	0.000302	0.000994	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CXCR4—sarcoma	0.000301	0.00099	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Doxorubicin—sarcoma	0.000301	0.00114	CcSEcCtD
Pimecrolimus—Oedema—Doxorubicin—sarcoma	0.000301	0.00114	CcSEcCtD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—SRC—sarcoma	0.0003	0.000989	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—SRC—sarcoma	0.0003	0.000989	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—HRAS—sarcoma	0.000299	0.000984	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—sarcoma	0.000299	0.000984	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—SRC—sarcoma	0.000299	0.000984	CbGpPWpGaD
Pimecrolimus—Infection—Doxorubicin—sarcoma	0.000299	0.00113	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000296	0.00112	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—CREB1—sarcoma	0.000296	0.000973	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Doxorubicin—sarcoma	0.000295	0.00112	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—sarcoma	0.000295	0.00097	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—EGFR—sarcoma	0.000294	0.000968	CbGpPWpGaD
Pimecrolimus—Skin disorder—Doxorubicin—sarcoma	0.000292	0.00111	CcSEcCtD
Pimecrolimus—Paraesthesia—Epirubicin—sarcoma	0.000292	0.00111	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—NRAS—sarcoma	0.00029	0.000956	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Epirubicin—sarcoma	0.00029	0.0011	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR—NRAS—sarcoma	0.000289	0.000951	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—NRAS—sarcoma	0.000288	0.000946	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—NRAS—sarcoma	0.000286	0.000942	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000285	0.000937	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—sarcoma	0.000282	0.000928	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—EGFR—sarcoma	0.000282	0.000926	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Epirubicin—sarcoma	0.000281	0.00106	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR in disease—SRC—sarcoma	0.00028	0.000921	CbGpPWpGaD
Pimecrolimus—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	0.00028	0.000921	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFC—sarcoma	0.000279	0.000918	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000279	0.000917	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—HRAS—sarcoma	0.000278	0.000915	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—KRAS—sarcoma	0.000278	0.000915	CbGpPWpGaD
Pimecrolimus—Constipation—Epirubicin—sarcoma	0.000278	0.00105	CcSEcCtD
Pimecrolimus—Pain—Epirubicin—sarcoma	0.000278	0.00105	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—SRC—sarcoma	0.000277	0.000913	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—EGFR—sarcoma	0.000277	0.000912	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—HRAS—sarcoma	0.000276	0.000909	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—SRC—sarcoma	0.000275	0.000905	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000274	0.00104	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—SRC—sarcoma	0.000274	0.000901	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Doxorubicin—sarcoma	0.00027	0.00102	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CD34—sarcoma	0.00027	0.000887	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—sarcoma	0.000269	0.000886	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—NRAS—sarcoma	0.000269	0.000886	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—NRAS—sarcoma	0.000269	0.000886	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Doxorubicin—sarcoma	0.000268	0.00102	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—NRAS—sarcoma	0.000267	0.000878	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—KRAS—sarcoma	0.000266	0.000875	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Epirubicin—sarcoma	0.000266	0.00101	CcSEcCtD
Pimecrolimus—MTOR—Disease—TLE1—sarcoma	0.000266	0.000874	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—EGFR—sarcoma	0.000265	0.000871	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—NRAS—sarcoma	0.000264	0.00087	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—sarcoma	0.000263	0.000866	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—EGFR—sarcoma	0.000263	0.000866	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—NRAS—sarcoma	0.000263	0.000866	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.000263	0.000866	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—EGFR—sarcoma	0.000262	0.000862	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—KRAS—sarcoma	0.000262	0.000861	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—EGFR—sarcoma	0.000261	0.000858	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—MDM2—sarcoma	0.000261	0.000858	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—sarcoma	0.00026	0.000984	CcSEcCtD
Pimecrolimus—Urticaria—Epirubicin—sarcoma	0.000258	0.000979	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—sarcoma	0.000257	0.000975	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—sarcoma	0.000257	0.000975	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—sarcoma	0.000257	0.000846	CbGpPWpGaD
Pimecrolimus—Abdominal pain—Epirubicin—sarcoma	0.000257	0.000974	CcSEcCtD
Pimecrolimus—Body temperature increased—Epirubicin—sarcoma	0.000257	0.000974	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—KRAS—sarcoma	0.00025	0.000823	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—NRAS—sarcoma	0.000249	0.00082	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—KRAS—sarcoma	0.000249	0.000819	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—sarcoma	0.000249	0.000819	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—SRC—sarcoma	0.000248	0.000816	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—KRAS—sarcoma	0.000248	0.000815	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—KRAS—sarcoma	0.000246	0.000811	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—sarcoma	0.000246	0.000932	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR in disease—EGFR—sarcoma	0.000245	0.000807	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—EGFR—sarcoma	0.000245	0.000807	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—sarcoma	0.000245	0.000807	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MDM2—sarcoma	0.000245	0.000805	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—EGFR—sarcoma	0.000243	0.0008	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—sarcoma	0.000243	0.000799	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—EGFR—sarcoma	0.000241	0.000793	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—EGFR—sarcoma	0.00024	0.000789	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NPM1—sarcoma	0.00024	0.000789	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Epirubicin—sarcoma	0.000239	0.000908	CcSEcCtD
Pimecrolimus—Urticaria—Doxorubicin—sarcoma	0.000239	0.000906	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—sarcoma	0.000238	0.000785	CbGpPWpGaD
Pimecrolimus—Abdominal pain—Doxorubicin—sarcoma	0.000238	0.000901	CcSEcCtD
Pimecrolimus—Body temperature increased—Doxorubicin—sarcoma	0.000238	0.000901	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—HRAS—sarcoma	0.000236	0.000778	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000234	0.00077	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FOXO1—sarcoma	0.000232	0.000765	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—HRAS—sarcoma	0.000232	0.000765	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PDGFRB—sarcoma	0.000232	0.000763	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—KRAS—sarcoma	0.000232	0.000763	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—KRAS—sarcoma	0.000232	0.000763	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	0.000232	0.000763	CbGpPWpGaD
Pimecrolimus—Pruritus—Epirubicin—sarcoma	0.00023	0.000872	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—KRAS—sarcoma	0.00023	0.000756	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PDGFRA—sarcoma	0.000228	0.000752	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—KRAS—sarcoma	0.000228	0.000749	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—EGFR—sarcoma	0.000227	0.000747	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—KRAS—sarcoma	0.000227	0.000746	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—JUN—sarcoma	0.000227	0.000746	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—sarcoma	0.000226	0.000744	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FOXO1—sarcoma	0.000223	0.000734	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FLT1—sarcoma	0.000223	0.000734	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PDGFRB—sarcoma	0.000223	0.000733	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—HRAS—sarcoma	0.000222	0.000732	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Epirubicin—sarcoma	0.000222	0.000843	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—FOXO1—sarcoma	0.000222	0.000731	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PDGFRB—sarcoma	0.000222	0.00073	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Doxorubicin—sarcoma	0.000222	0.00084	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—PLCG1—sarcoma	0.000219	0.000722	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PDGFRA—sarcoma	0.000219	0.000722	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PDGFRA—sarcoma	0.000218	0.000719	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	0.000217	0.000715	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—KRAS—sarcoma	0.000214	0.000706	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—HRAS—sarcoma	0.000214	0.000703	CbGpPWpGaD
Pimecrolimus—Pruritus—Doxorubicin—sarcoma	0.000213	0.000807	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—HRAS—sarcoma	0.000212	0.000699	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—sarcoma	0.000211	0.000696	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—HRAS—sarcoma	0.000211	0.000696	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCR4—sarcoma	0.000211	0.000693	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—HRAS—sarcoma	0.00021	0.000692	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—HRAS—sarcoma	0.000209	0.000689	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ATF1—sarcoma	0.000208	0.000686	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ENO2—sarcoma	0.000208	0.000683	CbGpPWpGaD
Pimecrolimus—Vomiting—Epirubicin—sarcoma	0.000207	0.000784	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—sarcoma	0.000206	0.000679	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Doxorubicin—sarcoma	0.000206	0.00078	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	0.000205	0.000675	CbGpPWpGaD
Pimecrolimus—Rash—Epirubicin—sarcoma	0.000205	0.000777	CcSEcCtD
Pimecrolimus—Dermatitis—Epirubicin—sarcoma	0.000205	0.000776	CcSEcCtD
Pimecrolimus—Headache—Epirubicin—sarcoma	0.000204	0.000772	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—sarcoma	0.000198	0.000651	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—HRAS—sarcoma	0.000197	0.000648	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	0.000197	0.000648	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HRAS—sarcoma	0.000197	0.000648	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—HRAS—sarcoma	0.000195	0.000642	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTPRC—sarcoma	0.000195	0.000642	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—sarcoma	0.000193	0.000637	CbGpPWpGaD
Pimecrolimus—Nausea—Epirubicin—sarcoma	0.000193	0.000732	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—HRAS—sarcoma	0.000193	0.000634	CbGpPWpGaD
Pimecrolimus—Vomiting—Doxorubicin—sarcoma	0.000191	0.000725	CcSEcCtD
Pimecrolimus—MTOR—Immune System—PLCG1—sarcoma	0.000191	0.000628	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—SRC—sarcoma	0.000191	0.000627	CbGpPWpGaD
Pimecrolimus—Rash—Doxorubicin—sarcoma	0.00019	0.000719	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—sarcoma	0.000189	0.000718	CcSEcCtD
Pimecrolimus—Headache—Doxorubicin—sarcoma	0.000188	0.000714	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—TLE1—sarcoma	0.000186	0.000612	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NRAS—sarcoma	0.000183	0.000604	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—HRAS—sarcoma	0.000182	0.0006	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ATF1—sarcoma	0.000181	0.000596	CbGpPWpGaD
Pimecrolimus—Nausea—Doxorubicin—sarcoma	0.000179	0.000677	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—KIT—sarcoma	0.000177	0.000583	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PLCG1—sarcoma	0.000176	0.00058	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	0.000174	0.000574	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KIT—sarcoma	0.00017	0.00056	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KIT—sarcoma	0.000169	0.000557	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CXCR4—sarcoma	0.000169	0.000557	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CREB1—sarcoma	0.000169	0.000555	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—EGFR—sarcoma	0.000167	0.00055	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF1R—sarcoma	0.000163	0.000538	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CREB1—sarcoma	0.000162	0.000533	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CREB1—sarcoma	0.000161	0.00053	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KRAS—sarcoma	0.000158	0.000519	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFC—sarcoma	0.000157	0.000517	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FOXO1—sarcoma	0.000156	0.000512	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PDGFRB—sarcoma	0.000155	0.000511	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PDGFRA—sarcoma	0.000153	0.000503	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—sarcoma	0.00015	0.000492	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MDM2—sarcoma	0.000139	0.000459	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FOXO1—sarcoma	0.000135	0.000445	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PDGFRB—sarcoma	0.000135	0.000445	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—HRAS—sarcoma	0.000134	0.000442	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—MDM2—sarcoma	0.000134	0.000441	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MDM2—sarcoma	0.000133	0.000439	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PDGFRA—sarcoma	0.000133	0.000438	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KDR—sarcoma	0.000129	0.000424	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FLT1—sarcoma	0.000125	0.000413	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FOXO1—sarcoma	0.000125	0.000411	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PDGFRB—sarcoma	0.000125	0.000411	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PLCG1—sarcoma	0.000123	0.000406	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PDGFRA—sarcoma	0.000123	0.000404	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—JUN—sarcoma	0.000121	0.000399	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CTNNB1—sarcoma	0.00012	0.000396	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KIT—sarcoma	0.000119	0.00039	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCR4—sarcoma	0.000119	0.00039	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ATF1—sarcoma	0.000117	0.000386	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CTNNB1—sarcoma	0.000115	0.000379	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CREB1—sarcoma	0.000113	0.000371	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—SRC—sarcoma	0.000109	0.000358	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRAS—sarcoma	0.000105	0.000344	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—SRC—sarcoma	0.000104	0.000344	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SRC—sarcoma	0.000104	0.000342	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KIT—sarcoma	0.000103	0.000339	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRAS—sarcoma	0.0001	0.000331	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRAS—sarcoma	0.0001	0.000329	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CREB1—sarcoma	9.82e-05	0.000323	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—sarcoma	9.53e-05	0.000314	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KIT—sarcoma	9.52e-05	0.000313	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MDM2—sarcoma	9.34e-05	0.000307	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—sarcoma	9.32e-05	0.000307	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1R—sarcoma	9.2e-05	0.000303	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—sarcoma	9.15e-05	0.000301	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—sarcoma	9.11e-05	0.0003	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CREB1—sarcoma	9.06e-05	0.000298	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—sarcoma	9e-05	0.000296	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FOXO1—sarcoma	8.75e-05	0.000288	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDGFRB—sarcoma	8.74e-05	0.000287	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—sarcoma	8.65e-05	0.000285	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—sarcoma	8.61e-05	0.000283	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDGFRA—sarcoma	8.6e-05	0.000283	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—sarcoma	8.34e-05	0.000275	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—sarcoma	8.13e-05	0.000268	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MDM2—sarcoma	8.12e-05	0.000267	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—JUN—sarcoma	8.12e-05	0.000267	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CTNNB1—sarcoma	8.06e-05	0.000265	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—sarcoma	7.65e-05	0.000252	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MDM2—sarcoma	7.5e-05	0.000247	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—sarcoma	7.35e-05	0.000242	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—sarcoma	7.32e-05	0.000241	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SRC—sarcoma	7.28e-05	0.00024	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—sarcoma	7.26e-05	0.000239	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KDR—sarcoma	7.24e-05	0.000238	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—sarcoma	7.09e-05	0.000233	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—JUN—sarcoma	7.06e-05	0.000232	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTNNB1—sarcoma	7.01e-05	0.000231	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRAS—sarcoma	7e-05	0.000231	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KIT—sarcoma	6.67e-05	0.000219	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—sarcoma	6.52e-05	0.000215	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CTNNB1—sarcoma	6.47e-05	0.000213	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—sarcoma	6.38e-05	0.00021	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CREB1—sarcoma	6.35e-05	0.000209	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SRC—sarcoma	6.33e-05	0.000208	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRAS—sarcoma	6.09e-05	0.000201	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—sarcoma	6.03e-05	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SRC—sarcoma	5.85e-05	0.000192	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRAS—sarcoma	5.63e-05	0.000185	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—sarcoma	5.55e-05	0.000183	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—sarcoma	5.36e-05	0.000176	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MDM2—sarcoma	5.25e-05	0.000173	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—sarcoma	5.24e-05	0.000173	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—sarcoma	5.24e-05	0.000172	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—sarcoma	5.13e-05	0.000169	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—sarcoma	5.12e-05	0.000169	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—sarcoma	4.84e-05	0.000159	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—sarcoma	4.69e-05	0.000154	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENO2—sarcoma	4.61e-05	0.000152	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HBA1—sarcoma	4.58e-05	0.000151	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—sarcoma	4.57e-05	0.000151	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JUN—sarcoma	4.57e-05	0.00015	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CTNNB1—sarcoma	4.53e-05	0.000149	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—sarcoma	4.46e-05	0.000147	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—sarcoma	4.12e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SRC—sarcoma	4.09e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—sarcoma	3.99e-05	0.000131	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRAS—sarcoma	3.94e-05	0.00013	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLCG1—sarcoma	3.91e-05	0.000129	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—sarcoma	3.67e-05	0.000121	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—sarcoma	3.59e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—sarcoma	3.39e-05	0.000112	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—sarcoma	3.01e-05	9.92e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—sarcoma	2.88e-05	9.48e-05	CbGpPWpGaD
